DYN - Dyne Therapeutics Inc Stock Price, Fair Value and News

$29.67-0.06 (-0.20%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

DYN Price Action

Last 7 days

4.5%

Last 30 days

-8.3%

Last 90 days

-36.2%

Trailing 12 Months

182.0%

DYN RSI Chart

DYN Valuation

Market Cap

3.0B

Price/Earnings (Trailing)

-10.25

Price/Sales (Trailing)

148.97

Price/Free Cashflow

-12.35

DYN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

DYN Fundamentals

DYN Revenue

Revenue (TTM)

20.3M

Rev. Growth (Yr)

323.76%

Rev. Growth (Qtr)

31.54%

DYN Earnings

Earnings (TTM)

-294.5M

Earnings Growth (Yr)

-61.31%

Earnings Growth (Qtr)

-49.19%

DYN Profitability

Return on Equity

-41.74%

Return on Assets

-38.31%

Free Cashflow Yield

-8.1%

DYN Investor Care

Shares Dilution (1Y)

65.81%

Diluted EPS (TTM)

-3.56

DYN Alerts

2 major insider sales recently.
CITADEL ADVISORS LLC reported owning 2.9% of DYN [2024-11-14]
JANUS HENDERSON GROUP PLC reported owning 6.8% of DYN [2024-11-14]

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	13.2M	20.3M	0
2023	4.2M	5.9M	7.2M	7.6M
2022	806.0K	1.0M	1.8M	2.9M
2021	190.0K	376.0K	560.0K	742.0K
2020	265.0K	240.0K	215.0K	0
2019	0	0	0	290.0K
2018	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Dyne Therapeutics Inc

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

CEO	Mr. Joshua T. Brumm
WEBSITE	dyne-tx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	134

Dyne Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Dyne Therapeutics Inc? What does DYN stand for in stocks?

DYN is the stock ticker symbol of Dyne Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Dyne Therapeutics Inc (DYN)?

As of Fri Nov 22 2024, market cap of Dyne Therapeutics Inc is 3.02 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DYN stock?

You can check DYN's fair value in chart for subscribers.

Is Dyne Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether DYN is over valued or under valued. Whether Dyne Therapeutics Inc is cheap or expensive depends on the assumptions which impact Dyne Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DYN.

What is Dyne Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Nov 22 2024, DYN's PE ratio (Price to Earnings) is -10.25 and Price to Sales (PS) ratio is 148.97. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DYN PE ratio will change depending on the future growth rate expectations of investors.